ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone Therapy in Men with Classical vs Functional Hypogonadism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 268440" data-attributes="member: 13851"><p><strong>Background and Significance</strong></p><p></p><p><em>Long-term data on Testosterone therapy (TTh) in hypogonadal men are limited and the clinical value, especially in men with functional hypogonadism (FH) is debated. <strong>A long-term, real-world registry study comprising groups of patients with hypogonadism of various etiologies provides a suitable and novel approach to this clinical issue. </strong></em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em>A registry spanning 9 years comprising 650 patients with hypogonadism included 188 patients with FH (mean age 42.3±11.3 years) and 462 men with classical hypogonadism(CH). Of these, 266 men had primary hypogonadism (PH, mean age 34.0±11.7 years) and 196 secondary hypogonadism (SH, mean age 31.9±12.0 years). <strong>All men uniformly received intramuscular T undecanoate (1000 mg). Effects of TTh on anthropometric parameters, as well as metabolic and safety parameters were compared. </strong></em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em><strong>The registry contained metabolic and safety parameters in the individual duration of TTh spanning 1 to 9 years. Serum T concentrations increased from 6.6±2.4 nmol/L to 19.3±2.9nmol/L in all patients (duration-of-treatment-dependentaverages, a mixed linear model for repeated measurements with the fixed variable “time x visit interaction”<0.001). In both categories of hypogonadism, TTh was associated with significant weight loss and a decrease in waist circumference (WC, both p<0.001). Cox regression andKaplan-Meier models revealed differences in interindividual check-points: men with FH were more likely to lose>10% weight and >5% of WC than men with CH (hazard ratio 1.3 [1.1-1.4], p=0.008 and hazard ratio 1.4[1.3-1.5], p=0.001).</strong> <strong>There was no difference between groups for the overall marked increase in hematocrit.</strong> <strong>Changes in PSA levels were more likely to occur in FH (hazard ratio 1.3 [1.1-1.6], p=0.003). During TTh, patients with FH exhibited significantly more pronounced changes of favorable nature in metabolic parameters than patients with CH (total cholesterol, triglycerides, LDL- and HDL-cholesterol, and fasting glucose). The same applied to scores of AMS and IIEF-EF questionnaires. Effects on most parameters, especially hematocrit, were significantly modulated by age and baseline values for weight, WC, and T. </strong></em></p><p></p><p></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><em>Findings regarding the effects and safety of TTh in different groups of hypogonadal men are provided. Effects on factors associated with cardiovascular health are modulated by diagnosis and age. Patients with FH seem to benefit to a larger extent from TTh, most likely attributable to their more pronounced risk factor profile at baseline.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 268440, member: 13851"] [B]Background and Significance[/B] [I]Long-term data on Testosterone therapy (TTh) in hypogonadal men are limited and the clinical value, especially in men with functional hypogonadism (FH) is debated. [B]A long-term, real-world registry study comprising groups of patients with hypogonadism of various etiologies provides a suitable and novel approach to this clinical issue. [/B][/I] [B]Methods[/B] [I]A registry spanning 9 years comprising 650 patients with hypogonadism included 188 patients with FH (mean age 42.3±11.3 years) and 462 men with classical hypogonadism(CH). Of these, 266 men had primary hypogonadism (PH, mean age 34.0±11.7 years) and 196 secondary hypogonadism (SH, mean age 31.9±12.0 years). [B]All men uniformly received intramuscular T undecanoate (1000 mg). Effects of TTh on anthropometric parameters, as well as metabolic and safety parameters were compared. [/B][/I] [B]Results[/B] [I][B]The registry contained metabolic and safety parameters in the individual duration of TTh spanning 1 to 9 years. Serum T concentrations increased from 6.6±2.4 nmol/L to 19.3±2.9nmol/L in all patients (duration-of-treatment-dependentaverages, a mixed linear model for repeated measurements with the fixed variable “time x visit interaction”<0.001). In both categories of hypogonadism, TTh was associated with significant weight loss and a decrease in waist circumference (WC, both p<0.001). Cox regression andKaplan-Meier models revealed differences in interindividual check-points: men with FH were more likely to lose>10% weight and >5% of WC than men with CH (hazard ratio 1.3 [1.1-1.4], p=0.008 and hazard ratio 1.4[1.3-1.5], p=0.001).[/B] [B]There was no difference between groups for the overall marked increase in hematocrit.[/B] [B]Changes in PSA levels were more likely to occur in FH (hazard ratio 1.3 [1.1-1.6], p=0.003). During TTh, patients with FH exhibited significantly more pronounced changes of favorable nature in metabolic parameters than patients with CH (total cholesterol, triglycerides, LDL- and HDL-cholesterol, and fasting glucose). The same applied to scores of AMS and IIEF-EF questionnaires. Effects on most parameters, especially hematocrit, were significantly modulated by age and baseline values for weight, WC, and T. [/B][/I] [B]Conclusions [I]Findings regarding the effects and safety of TTh in different groups of hypogonadal men are provided. Effects on factors associated with cardiovascular health are modulated by diagnosis and age. Patients with FH seem to benefit to a larger extent from TTh, most likely attributable to their more pronounced risk factor profile at baseline.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Testosterone Therapy in Men with Classical vs Functional Hypogonadism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top